Pancreatic Cancer Research

ResearcherNagoya UniversityActive in the last 2 years

Atsushi Enomoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9206-6116; OpenAlex author ID A5007226245, A5124829828. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2022: 6 papers · 2023: none · 2024: none · 2025: none · 2026: 4 papers

Papers 10

  1. Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1038/s41416-025-03299-5↗
  2. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  3. Compressive stress inhibits proliferation in AsPC-1 pancreatic cancer cells and reduction of Myc protein. Co-author DOI 10.1371/journal.pone.0352769↗
  4. Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
  5. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Co-author DOI 10.1007/s00428-021-03230-2↗
  6. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Last author DOI 10.1038/s41388-022-02288-9↗
  7. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Last author DOI 10.1038/s41388-022-02336-4↗
  8. Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Last author DOI 10.1111/pin.13198↗
  9. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial … Co-author DOI 10.1186/s12885-022-09272-2↗
  10. Good and Bad Stroma in Pancreatic Cancer: Relevance of Functional States of Cancer-Associated Fibroblasts. Last author DOI 10.3390/cancers14143315↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shinji Mii · 6 shared papers, 2022–2026 · strength 0.99
  2. Tadashi Iida · 5 shared papers, 2022 · strength 0.70
  3. Yasuyuki Mizutani · 5 shared papers, 2022 · strength 0.70
  4. Hisashi Haga · 3 shared papers, 2022–2026 · strength 0.59
  5. Atsushi Masamune · 3 shared papers, 2022–2026 · strength 0.42
  6. Takuya Ishikawa · 3 shared papers, 2022 · strength 0.38
  7. Hiroki Kawashima · 3 shared papers, 2022 · strength 0.38
  8. Eizaburo Ohno · 3 shared papers, 2022 · strength 0.38
  9. Mitsuhiro Fujishiro · 3 shared papers, 2022 · strength 0.38
  10. Masamichi Hayashi · 2 shared papers, 2022–2026 · strength 0.36
  11. Fuko Miyake · 1 shared paper, 2026 · strength 0.36
  12. Shoichiro Tange · 1 shared paper, 2026 · strength 0.36
  13. Ryota Ando · 2 shared papers, 2022 · strength 0.32
  14. Kunio Kataoka · 2 shared papers, 2022 · strength 0.30
  15. Reo Maruyama · 1 shared paper, 2026 · strength 0.25
  16. Keiko Shinjo · 1 shared paper, 2026 · strength 0.25
  17. Xingxing Wang · 1 shared paper, 2026 · strength 0.25
  18. Yutaka Kondo · 1 shared paper, 2026 · strength 0.25
  19. Yoshiki Hirooka · 2 shared papers, 2022 · strength 0.24
  20. Tomohisa Otsu · 1 shared paper, 2026 · strength 0.22
  21. Mitsuro Kanda · 1 shared paper, 2026 · strength 0.22
  22. Ryo Ashida · 1 shared paper, 2026 · strength 0.22
  23. Nobumasa Mizuno · 1 shared paper, 2026 · strength 0.22
  24. Motokazu Sugimoto · 1 shared paper, 2026 · strength 0.22
  25. Junpei Yamaguchi · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.